<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Exp Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">Clinical and Experimental Gastroenterology</journal-id><journal-title-group><journal-title>Clinical and Experimental Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1178-7023</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.2147/CEG.S50465</article-id><article-id pub-id-type="publisher-id">ceg-7-435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hereditary angioedema: what the gastroenterologist needs to know</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ali</surname><given-names>M Aamir</given-names></name><xref ref-type="aff" rid="af1-ceg-7-435"/></contrib><contrib contrib-type="author"><name><surname>Borum</surname><given-names>Marie L</given-names></name><xref ref-type="aff" rid="af1-ceg-7-435"/><xref ref-type="corresp" rid="c1-ceg-7-435"/></contrib></contrib-group><aff id="af1-ceg-7-435">Division of Gastroenterology and Liver Diseases, George Washington University, Washington, DC, USA</aff><author-notes><corresp id="c1-ceg-7-435">Correspondence: Marie L Borum, Division of Gastroenterology and Liver Diseases, The George Washington University Medical Center, 22nd and I Streets, NW, Third Floor, Washington, DC 20037, USA, Tel +1 202 741 3333, Fax +1 202 741 2169, Email <email>mborum@mfa.gwu.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2014</year></pub-date><volume>7</volume><fpage>435</fpage><lpage>445</lpage><permissions><copyright-statement>&#x000a9; 2014 Ali and Borum. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>Up to 93% of patients with hereditary angioedema (HAE) experience recurrent abdominal pain. Many of these patients, who often present to emergency departments, primary care physicians, general surgeons, or gastroenterologists, are misdiagnosed for years and undergo unnecessary testing and surgical procedures. Making the diagnosis of HAE can be challenging because symptoms and attack locations are often inconsistent from one episode to the next. Abdominal attacks are common and can occur without other attack locations. An early, accurate diagnosis is central to managing HAE. Unexplained abdominal pain, particularly when accompanied by swelling of the face and extremities, suggests the diagnosis of HAE. A family history and radiologic imaging demonstrating edematous bowel also support an HAE diagnosis. Once HAE is suspected, C4 and C1 esterase inhibitor (C1-INH) laboratory studies are usually diagnostic. Patients with HAE may benefit from recently approved specific treatments, including plasma-derived C1-INH or recombinant C1-INH, a bradykinin B2-receptor antagonist, or a kallikrein inhibitor as first-line therapy and solvent/detergent-treated or fresh frozen plasma as second-line therapy for acute episodes. Short-term or long-term prophylaxis with nanofiltered C1-INH or attenuated androgens will prevent or reduce the frequency and severity of episodes. Gastroenterologists can play a critical role in identifying and treating patients with HAE, and should have a high index of suspicion when encountering patients with recurrent, unexplained bouts of abdominal pain. Given the high rate of abdominal attacks in HAE, it is important for gastroenterologists to appropriately diagnose and promptly recognize and treat HAE, or refer patients with HAE to an allergist.</p></abstract><kwd-group><title>Keywords</title><kwd>hereditary angioedema</kwd><kwd>abdominal pain</kwd><kwd>diagnosis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hereditary angioedema (HAE) is a potentially life-threatening disease that may go unrecognized or be misdiagnosed for an average of 8 years before the correct diagnosis is established.<xref rid="b1-ceg-7-435" ref-type="bibr">1</xref> Abdominal symptoms are extremely common, occurring in the majority (93%) of patients with HAE,<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref> and may be the only manifestation of the disease. Patients with HAE may initially present with recurrent episodes of abdominal pain and distension, nausea, vomiting, and diarrhea.<xref rid="b3-ceg-7-435" ref-type="bibr">3</xref>,<xref rid="b4-ceg-7-435" ref-type="bibr">4</xref></p><p>Because abdominal symptoms may precede by several years the episodes of subcutaneous tissue swelling that are characteristic of HAE, patients may undergo inappropriate surgical and medical treatment for any of a wide range of presumptive, incorrect diagnoses, including acute abdomen, biliary colic, hepatitis, regional enteritis, pancreatitis, cholecystitis, choledocholithiasis, nephrolithiasis, pyelonephritis, ruptured ovarian cyst, intestinal obstruction, duodenal ulcer, and ulcerative colitis.<xref rid="b3-ceg-7-435" ref-type="bibr">3</xref>,<xref rid="b4-ceg-7-435" ref-type="bibr">4</xref> Patients who develop abdominal symptoms related to HAE are usually seen by gastroenterologists, emergency department physicians, primary care physicians, and general surgeons.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref> Given that the majority of patients with HAE experience abdominal attacks, it is important for gastroenterologists to appropriately diagnose and promptly recognize and treat HAE or refer patients with HAE to an allergist.<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref> This review highlights HAE, its clinical presentation, and the role of the gastroenterologist in its diagnosis and management.</p></sec><sec><title>Disease burden</title><p>Patients with HAE who are seen in the emergency department often require hospitalization, considerably increasing the cost of care for each attack.<xref rid="b6-ceg-7-435" ref-type="bibr">6</xref> Review of a national database has shown that between 2006 and 2007 there were 5,040 emergency department visits by patients with HAE at a mean cost of $1,479 per visit, and with 41% of these visits requiring hospitalization.<xref rid="b6-ceg-7-435" ref-type="bibr">6</xref> Similarly, in a 4-year analysis of the epidemiology of HAE, there were 10,125 hospitalizations, with a mean length of stay of 5 days and mean charges of $22,728.<xref rid="b7-ceg-7-435" ref-type="bibr">7</xref> HAE is also associated with a high rate of morbidity, with many patients experiencing depression and poor health-related quality of life. HAE also negatively affects educational and career opportunities and reduces work productivity, compounding the substantial economic burden of HAE.<xref rid="b8-ceg-7-435" ref-type="bibr">8</xref></p></sec><sec><title>Types and pathophysiology</title><p>Estimates of the incidence of HAE worldwide vary from one in 10,000 to one in 150,000 persons.<xref rid="b9-ceg-7-435" ref-type="bibr">9</xref>,<xref rid="b10-ceg-7-435" ref-type="bibr">10</xref> In a retrospective review of patients with HAE, the median age at disease onset was 11.2 years, 93.3% of patients had recurrent abdominal pain, and women experienced a higher number of episodes per year than men.<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref> HAE is caused by mutations in the C1 esterase inhibitor (<italic>C1-INH</italic>) gene, also known as the <italic>SERPING1</italic> gene, which has been mapped to chromosome 11.<xref rid="b11-ceg-7-435" ref-type="bibr">11</xref> A known family history is present in 75% of cases, with an autosomal dominant inheritance pattern; in the remaining 25% of cases, the disease results from spontaneous mutations.<xref rid="b12-ceg-7-435" ref-type="bibr">12</xref>&#x02013;<xref rid="b14-ceg-7-435" ref-type="bibr">14</xref> Two types of HAE due to C1-INH deficiency have been characterized. Type I HAE accounts for 85% of cases and is due to mutations that result in decreased antigenic levels of functionally normal C1-INH. Type II HAE accounts for 15% of cases and is due to mutations that lead to levels of C1-INH that are normal but that have dysfunctional C1-INH proteins.<xref rid="b15-ceg-7-435" ref-type="bibr">15</xref> So far, more than 200 different mutations that cause HAE have been identified.<xref rid="b16-ceg-7-435" ref-type="bibr">16</xref>,<xref rid="b17-ceg-7-435" ref-type="bibr">17</xref></p><p>A third type of HAE (HAE with normal C1-INH) has been identified, in which the level and activity of C1-INH are normal and there is no characteristic laboratory profile. The clinical presentation of this type of HAE is indistinguishable from types I and II; however, this third type tends to develop later in life. In some patients, this subtype is associated with a mutation in the coagulation factor XII gene, with subsequent increased levels of bradykinin. Estrogen exacerbates the severity of disease in patients with HAE who have normal C1-INH, and edema appears to be estrogen-dependent in a subset of patients.<xref rid="b18-ceg-7-435" ref-type="bibr">18</xref>,<xref rid="b19-ceg-7-435" ref-type="bibr">19</xref></p><p>The underlying mechanism for HAE types I and II is functional impairment of C1-INH, a protease inhibitor that regulates complement activation (C1r, C1s, and mannose-binding lectin-associated serine protease [MASP]-1 and MASP-2), contact system activation (factor XII and kallikrein), and inactivation of several fibrinolytic (tissue plasminogen activator and plasmin) and coagulation (factor XI and thrombin) proteases.<xref rid="b16-ceg-7-435" ref-type="bibr">16</xref>,<xref rid="b20-ceg-7-435" ref-type="bibr">20</xref>,<xref rid="b21-ceg-7-435" ref-type="bibr">21</xref> Of the four systems regulated by C1-INH, regulation of plasma kallikrein, the enzyme that releases bradykinin from kininogen, is responsible for the development of angioedema. A deficiency in C1-INH leads to unregulated plasma kallikrein activity, with subsequent overproduction of bradykinin that enhances vasodilation and vascular permeability, causing extravasation of plasma into interstitial tissue, leading to angioedema.<xref rid="b18-ceg-7-435" ref-type="bibr">18</xref>,<xref rid="b22-ceg-7-435" ref-type="bibr">22</xref> The kallikrein-kinin system has a central role in several other systems, including the clotting cascade, vasodilation, vascular permeability, and activation of the renin-angiotensin-aldosterone system.<xref rid="b21-ceg-7-435" ref-type="bibr">21</xref>,<xref rid="b23-ceg-7-435" ref-type="bibr">23</xref>,<xref rid="b24-ceg-7-435" ref-type="bibr">24</xref>
<xref ref-type="fig" rid="f1-ceg-7-435">Figure 1</xref> shows the dysregulation of the coagulation, complement, and contact cascades in HAE.<xref rid="b25-ceg-7-435" ref-type="bibr">25</xref></p></sec><sec><title>Clinical presentation of type I and type II HAE</title><p>Precipitating factors for HAE episodes may include medications such as oral contraceptives or angiotensin-converting enzyme inhibitors, infection, trauma, hormonal changes, and surgical, endoscopic, or dental procedures.<xref rid="b18-ceg-7-435" ref-type="bibr">18</xref>,<xref rid="b26-ceg-7-435" ref-type="bibr">26</xref>,<xref rid="b27-ceg-7-435" ref-type="bibr">27</xref> Depending on the underlying cause of angioedema, an untreated attack will typically resolve within 1&#x02013;5 days; however, episodes involving the abdomen or upper airways may require acute treatment to alleviate pain, nausea, and vomiting, in the case of abdominal angioedema, and to prevent death, in the case of respiratory symptoms.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref> The site of an HAE attack varies between patients and may also vary within the same patient.<xref rid="b28-ceg-7-435" ref-type="bibr">28</xref> The most common symptoms of HAE are recurrent abdominal symptoms, occurring in about 93% of patients, and diffuse skin edema, particularly in the extremities, occurring in 97.5% of patients.<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref> The lips, eyelids, tongue, or genitalia may also be affected.<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref>,<xref rid="b28-ceg-7-435" ref-type="bibr">28</xref> The frequency and distribution of symptoms experienced by patients during an HAE attack are shown in <xref ref-type="fig" rid="f2-ceg-7-435">Figure 2</xref>.<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref></p><p>HAE may also present with episodic, recurrent, unexplained abdominal attacks that involve symptoms of tender, crampy pain and nausea or vomiting.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref>,<xref rid="b29-ceg-7-435" ref-type="bibr">29</xref>,<xref rid="b30-ceg-7-435" ref-type="bibr">30</xref> The abdominal pain experienced by patients with HAE may be severe and acute in onset, or may be recurrent and chronic and of moderate severity.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref>,<xref rid="b29-ceg-7-435" ref-type="bibr">29</xref> The diarrhea is caused by edema of the gut that may result in extravascular fluid loss, leading to hypotension and shock in some patients.<xref rid="b29-ceg-7-435" ref-type="bibr">29</xref> In a prospective and retrospective analysis of 153 patients with HAE, pain caused by abdominal attacks was characterized by its intensity, quality, and time course, and was described as having four phases, as well as a prephase (phase 0) in which patients had extra-abdominal symptoms but not abdominal pain (<xref ref-type="fig" rid="f3-ceg-7-435">Figure 3</xref>).<xref rid="b30-ceg-7-435" ref-type="bibr">30</xref> Phase 1 was the time from the first abdominal complaint to the onset of crampy pain; phase 2 was the time between the initial crampy pain and its peak; phase 3 was the time of maximum symptoms; and phase 4 was the time from the beginning of symptom relief to complete resolution of symptoms.<xref rid="b30-ceg-7-435" ref-type="bibr">30</xref> The mean duration of phase 1 was 3.3 hours, during which patients had a wide range of symptoms, which included a feeling of satiety, abdominal distension, and nausea. All patients developed worsening crampy pain during phase 2, with the mean time to maximal pain being 2.4 hours. The median duration of the maximal pain phase was 23.5 hours, with crampy pain occurring in all patients, scored as severe to excruciating in 87% of patients and associated with vomiting and diarrhea in 78% and 65% of patients, respectively. The mean time to complete resolution of symptoms was 45.0 hours. Review of the character of the pain symptoms in these patients showed the presence of two different types of abdominal pain attack, ie, an upper gastrointestinal type and a lower gastrointestinal type. Patients with the upper gastrointestinal type of abdominal pain from HAE had extreme pain, nausea, vomiting, and hypotension in the absence of diarrhea; patients with the lower gastrointestinal type of abdominal attack had crampy pain and diarrhea, but no vomiting or hypotension. Other less frequent but potentially serious symptoms or complications in patients with HAE experiencing an abdominal attack have included circulatory collapse and shock due to hypovolemia, persistent noncrampy abdominal pain, dysuria, bloody diarrhea, intussusceptions, and tetany.<xref rid="b30-ceg-7-435" ref-type="bibr">30</xref></p><p>The abdominal symptoms of HAE are often similar to those of an acute abdomen, sometimes prompting exploratory abdominal surgery; as a result, approximately one third of patients with undiagnosed HAE undergo unnecessary surgery at the time of an abdominal attack.<xref rid="b31-ceg-7-435" ref-type="bibr">31</xref> Even after HAE has been diagnosed, distinguishing between an abdominal attack and a surgical emergency can be difficult.<xref rid="b31-ceg-7-435" ref-type="bibr">31</xref> In one case, a 46-year-old woman presented with recurrent abdominal pain and edema several years before developing intermittent, localized episodes of limb, trunk, neck, and facial swelling. She had undergone numerous surgical procedures for a variety of diagnoses, including pancreatitis, cholecystitis, common bile duct stone, ruptured ovarian cyst, renal stone, intestinal obstruction, pyelonephritis, duodenal ulcer, and ulcerative colitis before HAE was ultimately diagnosed.<xref rid="b3-ceg-7-435" ref-type="bibr">3</xref> In another case study, a 34-year-old woman who presented to the emergency department with severe abdominal cramping on several occasions was treated for presumed gastroenteritis; this patient, too, was later found to have HAE.<xref rid="b32-ceg-7-435" ref-type="bibr">32</xref> In a recent retrospective study, significant leukocytosis with neutrophilia and high hematocrit levels and no elevations in C-reactive protein levels were present in all patients with HAE during an acute gastrointestinal attack,<xref rid="b33-ceg-7-435" ref-type="bibr">33</xref> suggesting that such a laboratory profile may be a consideration in the differential diagnosis of HAE.</p><p>Upper airway edema with asphyxiation is a potentially fatal clinical presentation of HAE.<xref rid="b34-ceg-7-435" ref-type="bibr">34</xref> Although often referred to as &#x0201c;laryngeal edema,&#x0201d; upper airway edema often involves the mucosa of the mesopharynx and hypopharynx.<xref rid="b35-ceg-7-435" ref-type="bibr">35</xref> Interestingly, however, the formation of edema spares the mucosa of the nasal cavity and paranasal sinuses. In many cases, the exact anatomic location of swelling remains uncharted, because during attacks patients are only rarely seen by ear, nose, and throat specialists.<xref rid="b35-ceg-7-435" ref-type="bibr">35</xref> Upper airway edema may occur in approximately half of all patients with HAE at least once in their lives.<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref> Upper airway edema has been associated with a high mortality rate, which has improved with appropriate diagnosis and treatment.<xref rid="b29-ceg-7-435" ref-type="bibr">29</xref></p></sec><sec><title>Diagnosis</title><p>The diagnosis of HAE is often delayed due to low awareness of the disease; however, unacceptable delays in diagnosis have been reported even when a family history of HAE is known.<xref rid="b36-ceg-7-435" ref-type="bibr">36</xref> Gastroenterologists should consider a diagnosis of angioedema in all patients presenting with episodic, recurrent, unexplained abdominal attacks that involve symptoms of tender, crampy pain, and nausea or vomiting (<xref ref-type="table" rid="t1-ceg-7-435">Table 1</xref>).<xref rid="b26-ceg-7-435" ref-type="bibr">26</xref>,<xref rid="b30-ceg-7-435" ref-type="bibr">30</xref>,<xref rid="b32-ceg-7-435" ref-type="bibr">32</xref> Between abdominal attacks, the patient with HAE is completely asymptomatic, unlike patients with functional bowel disorders. Analysis of the history should attempt to identify triggers for the symptoms, such as medications, allergens, trauma, or infection, and to identify either a personal or family history of HAE. Although the presence of a family history is helpful in making the diagnosis, the absence of a family history does not rule out the condition, because 25% of cases are the result of spontaneous mutations.<xref rid="b13-ceg-7-435" ref-type="bibr">13</xref> During an acute episode, the physical examination may show marked abdominal distension; possible cutaneous swelling; diffuse or localized tenderness, sometimes with rebound; and shifting dullness with possible ascites.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref> Urticaria and pruritus are not present and are seen only in allergic forms of angioedema,<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref> although in some patients, erythema marginatum precedes acute events and may be misdiagnosed as urticaria.<xref rid="b37-ceg-7-435" ref-type="bibr">37</xref>,<xref rid="b38-ceg-7-435" ref-type="bibr">38</xref></p><p>Imaging studies for the diagnosis of HAE involving the abdomen include plain radiographs, ultrasonography, contrast-enhanced computed tomography (CT), and magnetic resonance imaging of the abdomen.<xref rid="b39-ceg-7-435" ref-type="bibr">39</xref> An abdominal CT scan in a patient with HAE may show thickening of the bowel wall and mucosa and an increase in enhancement when a contrast agent is used (<xref ref-type="fig" rid="f4-ceg-7-435">Figure 4</xref>).<xref rid="b39-ceg-7-435" ref-type="bibr">39</xref> An abdominal CT scan may also show more layers of the small bowel than are normally visible and more prominent mesenteric vessels and ascites. Abdominal ultrasonography is useful for confirming the accumulation of fluid in the peritoneal cavity during an attack and for early detection of adverse effects of therapy,<xref rid="b40-ceg-7-435" ref-type="bibr">40</xref>,<xref rid="b41-ceg-7-435" ref-type="bibr">41</xref> and may be less expensive and more readily available than CT. A CT scan or ultrasonography is usually sufficient to diagnose angioedema of the abdomen,<xref rid="b27-ceg-7-435" ref-type="bibr">27</xref>,<xref rid="b42-ceg-7-435" ref-type="bibr">42</xref> and magnetic resonance imaging may be necessary with manifestations of potential cerebral edema.<xref rid="b43-ceg-7-435" ref-type="bibr">43</xref></p><p>Capsule endoscopy can provide rapid visual confirmation of bowel occlusion due to HAE<xref rid="b44-ceg-7-435" ref-type="bibr">44</xref> and may be a useful diagnostic tool. When HAE is suspected or known, proper prophylactic measures must be taken to prevent induction or exacerbation of potentially life-threatening oropharyngeal edema.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref></p><p>Laboratory evaluation for HAE should include measurement of C4 complement, concentration of C1-INH, and functional measurement of C1-INH (see <xref ref-type="table" rid="t1-ceg-7-435">Table 1</xref>). C4 levels are typically less than 30% of mean normal levels, which usually range from 0.15 to 0.65 g/L in untreated HAE.<xref rid="b45-ceg-7-435" ref-type="bibr">45</xref> Because C4 levels have a high sensitivity and negative predictive value for the disease, they are considered to be a good screening test for HAE.<xref rid="b45-ceg-7-435" ref-type="bibr">45</xref>,<xref rid="b46-ceg-7-435" ref-type="bibr">46</xref> C1-INH antigen levels are low in type I HAE and are normal or high in type II HAE.<xref rid="b15-ceg-7-435" ref-type="bibr">15</xref></p><p>If either the C1-INH concentration or functions are low in an individual with low C4 levels, the tests should be repeated before making the diagnosis, to minimize false positive results.<xref rid="b45-ceg-7-435" ref-type="bibr">45</xref> Given the high negative predictive value of C4, the diagnosis of HAE should be questioned in individuals with normal C4 and low C1-INH concentration or function.<xref rid="b15-ceg-7-435" ref-type="bibr">15</xref>,<xref rid="b45-ceg-7-435" ref-type="bibr">45</xref>,<xref rid="b46-ceg-7-435" ref-type="bibr">46</xref> Normal C4 levels and normal C1-INH concentration and function in patients with a clinical presentation consistent with HAE should prompt an evaluation for HAE with normal C1-INH.<xref rid="b47-ceg-7-435" ref-type="bibr">47</xref>,<xref rid="b48-ceg-7-435" ref-type="bibr">48</xref> A thorough patient history, along with imaging and laboratory evaluations, is critical to successfully making a differential diagnosis of acute HAE and initiating prompt and appropriate treatment (<xref ref-type="fig" rid="f5-ceg-7-435">Figure 5</xref>).<xref rid="b49-ceg-7-435" ref-type="bibr">49</xref>,<xref rid="b50-ceg-7-435" ref-type="bibr">50</xref></p></sec><sec><title>Treatment</title><sec><title>Current awareness of treatment</title><p>Once a patient is diagnosed with HAE, the gastroenterologist should involve an allergist or immunologist to guide the long-term management of the patient.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref> Patients should be well trained for self-administration of medications and should be advised to wear a medical bracelet or carry a wallet card detailing their treatment plan in the event of an acute HAE attack.<xref rid="b51-ceg-7-435" ref-type="bibr">51</xref>,<xref rid="b52-ceg-7-435" ref-type="bibr">52</xref> Several evidence-based management guidelines and recommendations have been developed for the acute and prophylactic treatment of angioedema due to C1-INH deficiency.<xref rid="b47-ceg-7-435" ref-type="bibr">47</xref>,<xref rid="b53-ceg-7-435" ref-type="bibr">53</xref>&#x02013;<xref rid="b55-ceg-7-435" ref-type="bibr">55</xref> Management guidelines from the Hereditary Angioedema International Working Group are shown in <xref ref-type="table" rid="t2-ceg-7-435">Table 2</xref>.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref></p></sec><sec><title>Acute treatment</title><p>Assessment and maintenance of the airway should be the first consideration in the setting of acute episodes of HAE because angioedema involving the airway can be potentially life-threatening. Physicians should consider intubation at the first signs of airway compromise because laryngeal edema may worsen during the attack, making endotracheal intubation difficult.<xref rid="b56-ceg-7-435" ref-type="bibr">56</xref> Gastrointestinal attacks can be painful and debilitating, and in extreme cases (eg, hypovolemia) can be life-threatening. Although disfiguring and painful, cutaneous attacks are not associated with serious complications.</p><p>According to several recent evidence-based recommendations, the first-line treatment option for acute episodes of HAE is a C1-INH replacement product.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref>,<xref rid="b55-ceg-7-435" ref-type="bibr">55</xref>,<xref rid="b57-ceg-7-435" ref-type="bibr">57</xref> Two plasma-derived nanofiltered C1-INH products and one recombinant C1-INH product are currently available for the treatment of acute episodes of HAE<xref rid="b58-ceg-7-435" ref-type="bibr">58</xref> (<xref ref-type="table" rid="t3-ceg-7-435">Table 3</xref>). Berinert<sup>&#x000ae;</sup> P (CSL Behring, Kankakee, IL, USA) is a plasma-derived nanofiltered C1-INH approved in Europe for self-administration to treat all acute attacks and for preprocedure prevention of attacks, and in the US for treatment of acute facial, laryngeal, and abdominal attacks of HAE.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref>,<xref rid="b58-ceg-7-435" ref-type="bibr">58</xref>,<xref rid="b59-ceg-7-435" ref-type="bibr">59</xref> Cinryze<sup>&#x000ae;</sup> (ViroPharma Biologics, Exton, PA, USA) is another nanofiltered, plasma-derived C1-INH that is approved in Europe for treating all acute attacks of HAE and for short-term and long-term prophylaxis, and in the US for routine prophylaxis.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref>,<xref rid="b60-ceg-7-435" ref-type="bibr">60</xref> Cetor<sup>&#x000ae;</sup> (Sanquin Blood Supply Foundation, Amsterdam, the Netherlands), another C1-INH, was approved in 1997 in a few European countries but has never been tested in clinical trials.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref>,<xref rid="b61-ceg-7-435" ref-type="bibr">61</xref></p><p>Ruconest<sup>&#x000ae;</sup> (conestat alfa; Pharming Group NV, Leiden, the Netherlands) is a human recombinant C1-INH derived from the milk of transgenic rabbits with the same inhibitory profile as plasma-derived C1-INH.<xref rid="b62-ceg-7-435" ref-type="bibr">62</xref>,<xref rid="b63-ceg-7-435" ref-type="bibr">63</xref> This recombinant C1-INH is effective in relieving symptoms of acute angioedema and is approved in Europe for the acute treatment of HAE.<xref rid="b62-ceg-7-435" ref-type="bibr">62</xref> Ruconest is undergoing clinical trials in the US and at the time of this writing was under review by the US Food and Drug Administration for the treatment of acute attacks of HAE.<xref rid="b64-ceg-7-435" ref-type="bibr">64</xref></p><p>Ecallantide (Kalbitor<sup>&#x000ae;</sup>; Dyax Corp, Burlington, MA, USA) is a recombinant protein, synthesized in yeast, that is a potent, specific, and reversible inhibitor of plasma kallikrein.<xref rid="b65-ceg-7-435" ref-type="bibr">65</xref>,<xref rid="b66-ceg-7-435" ref-type="bibr">66</xref> Ecallantide binds to plasma kallikrein and directly inhibits conversion of high-molecular-weight kininogen to bradykinin.<xref rid="b65-ceg-7-435" ref-type="bibr">65</xref> Because elevated levels of bradykinin are essential for the development of symptoms of HAE,<xref rid="b65-ceg-7-435" ref-type="bibr">65</xref> inhibition of bradykinin release is an important mechanism for treating attacks of HAE. Ecallantide is administered subcutaneously and is rapidly distributed throughout the vascular compartment.<xref rid="b22-ceg-7-435" ref-type="bibr">22</xref>,<xref rid="b67-ceg-7-435" ref-type="bibr">67</xref> Ecallantide is approved in the US for the treatment of acute attacks of HAE.<xref rid="b65-ceg-7-435" ref-type="bibr">65</xref></p><p>Icatibant (Firazyr<sup>&#x000ae;</sup>; Shire Orphan Therapies, Inc, Lexington, MA, USA) is a selective, competitive bradykinin B2 receptor antagonist that acts as a bradykinin inhibitor and is administered by subcutaneous injection in the abdominal area.<xref rid="b68-ceg-7-435" ref-type="bibr">68</xref>,<xref rid="b69-ceg-7-435" ref-type="bibr">69</xref> Icatibant is approved for the acute treatment of HAE in Europe and in the US.<xref rid="b68-ceg-7-435" ref-type="bibr">68</xref>&#x02013;<xref rid="b70-ceg-7-435" ref-type="bibr">70</xref></p><p>According to Hereditary Angioedema International Working Group consensus recommendations, patients with HAE should have access to any one of these medications on demand for use during any type of HAE attack and should be trained to self-administer the medication.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref> However, if laryngeal symptoms persist following treatment, patients should report to a hospital immediately.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref></p><p>Second-line therapies in the absence of first-line agents or if the patient cannot tolerate them include solvent/detergent-treated plasma or fresh frozen plasma.<xref rid="b57-ceg-7-435" ref-type="bibr">57</xref>,<xref rid="b71-ceg-7-435" ref-type="bibr">71</xref> No controlled clinical trials have been conducted on the efficacy of plasma for the treatment of HAE; however, reports of successful resolution of acute exacerbations have been published in case studies.<xref rid="b72-ceg-7-435" ref-type="bibr">72</xref>,<xref rid="b73-ceg-7-435" ref-type="bibr">73</xref> Disease transmission with plasma products remains a concern, and fresh frozen plasma may exacerbate angioedema.<xref rid="b57-ceg-7-435" ref-type="bibr">57</xref></p></sec></sec><sec><title>Prophylaxis</title><p>Although acute events can be unpredictable, certain triggers for acute HAE, such as environmental allergens, medications, surgeries, or childbirth, can be managed effectively.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref>,<xref rid="b53-ceg-7-435" ref-type="bibr">53</xref>,<xref rid="b71-ceg-7-435" ref-type="bibr">71</xref> Prophylactic therapy for HAE is warranted for both short-term use prior to precipitating events such as dental or surgical procedures and for long-term use in high-risk patients, ie, those with frequent or severe episodes and those whose symptoms cannot be controlled with on-demand therapy (see <xref ref-type="table" rid="t2-ceg-7-435">Table 2</xref>).</p><p>In patients with suspected HAE, endoscopy of the gastrointestinal tract or oropharynx is not recommended due to the risk of inducing a potentially life-threatening laryngeal attack.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref> If warranted for additional clinical reasons, prophylactic measures to protect the patient against laryngeal swelling should be initiated.<xref rid="b5-ceg-7-435" ref-type="bibr">5</xref></p><p>Attenuated androgens and nanofiltered C1-INH are the only treatments for the prophylaxis of HAE approved by the US Food and Drug Administration. Attenuated androgens such as danazol, oxandrolone, and stanozolol<xref rid="b50-ceg-7-435" ref-type="bibr">50</xref> work by increasing the levels of aminopeptidase P, which inactivates kinins and thereby increases production of C1-INH in the liver, and contributes to the protective effects of androgens against attacks of angioedema.<xref rid="b74-ceg-7-435" ref-type="bibr">74</xref>,<xref rid="b75-ceg-7-435" ref-type="bibr">75</xref> Androgens can be used effectively and safely for the short-term prophylaxis of HAE.<xref rid="b76-ceg-7-435" ref-type="bibr">76</xref> Long-term prophylaxis with androgens is associated with numerous adverse events, including weight gain, lipid abnormalities, liver cysts, hepatic adenomas and carcinomas, myopathies, hematuria, headaches, abnormal menses, hair loss or gain, increased or decreased libido, and anxiety.<xref rid="b50-ceg-7-435" ref-type="bibr">50</xref>,<xref rid="b76-ceg-7-435" ref-type="bibr">76</xref> The side effects of attenuated androgens can be minimized by titrating down to the minimal effective dose.<xref rid="b77-ceg-7-435" ref-type="bibr">77</xref></p><p>Owing to the risk of adverse events in patients taking attenuated androgens, currently the preferred therapy for both short-term and long-term HAE prophylaxis is nanofiltered C1-INH.<xref rid="b78-ceg-7-435" ref-type="bibr">78</xref> In a randomized trial evaluating the efficacy of C1-INH for the prophylaxis of HAE attacks, patients treated with C1-INH had an average decrease of 6.47 attacks (<italic>P</italic>&#x0003c;0.001) compared with patients receiving placebo over the 12-week evaluation period.<xref rid="b78-ceg-7-435" ref-type="bibr">78</xref> Treatment with C1-INH significantly reduced the frequency, severity, and duration of attacks, the number of rescue treatments of C1-INH needed, and the number of days of swelling.<xref rid="b78-ceg-7-435" ref-type="bibr">78</xref></p><p>Antifibrinolytic agents are not commonly used in the US. Agents such as tranexamic acid and epsilon-aminocaproic acid are chemically synthesized and exert their action in HAE by inhibiting conversion of plasminogen to plasmin.<xref rid="b50-ceg-7-435" ref-type="bibr">50</xref> These agents have been used for short-term and long-term prophylaxis,<xref rid="b57-ceg-7-435" ref-type="bibr">57</xref>,<xref rid="b75-ceg-7-435" ref-type="bibr">75</xref> although they are the least effective of the available therapeutic modalities and not recommended based on recent data.<xref rid="b57-ceg-7-435" ref-type="bibr">57</xref> The dosing recommendation for tranexamic acid is 25 mg 2&#x02013;3 times a day, not to exceed 6 g/day for the goal. Although prophylaxis reduces the occurrence of edematous episodes, it should be emphasized that life-threatening attacks may nevertheless occur.<xref rid="b50-ceg-7-435" ref-type="bibr">50</xref></p></sec><sec><title>Conclusion</title><p>Gastroenterologists are likely to be consulted when patients with HAE are hospitalized for acute HAE attacks involving abdominal symptoms, and may also see patients with HAE in the clinic when they are referred from the emergency department after an attack, usually during asymptomatic periods. The consequences of a missed diagnosis of HAE are considerable, with undiagnosed patients likely visiting the emergency department and undergoing hospitalization and even unnecessary surgical procedures. Furthermore, inadequately treated attacks may progress, resulting in needless significant additional morbidity and even mortality. However, because abdominal pain is often associated with HAE, a high index of suspicion should be maintained for this diagnosis, and a family history should be elicited and appropriate imaging and laboratory studies obtained. In this way, gastroenterologists can promptly diagnose and treat HAE and proceed to make the appropriate referral to an allergist, who can manage this potentially life-threatening disease with current treatment.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>In developing this manuscript, writing and editorial assistance with copyediting, formatting, and the creation of tables and figures was provided by Connexion Healthcare (Newtown, PA, USA). The manuscript was financially supported by Dyax Corp (Burlington, MA, USA).</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ceg-7-435"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunn</surname><given-names>ML</given-names></name><name><surname>Santos</surname><given-names>CB</given-names></name><name><surname>Craig</surname><given-names>TJ</given-names></name></person-group><article-title>Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?</article-title><source>Ann Allergy Asthma Immunol</source><year>2010</year><volume>104</volume><issue>3</issue><fpage>211</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">20377110</pub-id></element-citation></ref><ref id="b2-ceg-7-435"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>G</given-names></name><name><surname>Staubach</surname><given-names>P</given-names></name><name><surname>Hardt</surname><given-names>J</given-names></name></person-group><article-title>Hereditary angioedema: new findings concerning symptoms, affected organs, and course</article-title><source>Am J Med</source><year>2006</year><volume>119</volume><issue>3</issue><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">16490473</pub-id></element-citation></ref><ref id="b3-ceg-7-435"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feller</surname><given-names>EJ</given-names></name><name><surname>Spiro</surname><given-names>HM</given-names></name><name><surname>Katz</surname><given-names>LA</given-names></name></person-group><article-title>Hereditary angioneurotic oedema: an unusual cause of recurring abdominal pain</article-title><source>Gut</source><year>1970</year><volume>11</volume><issue>12</issue><fpage>983</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">5511819</pub-id></element-citation></ref><ref id="b4-ceg-7-435"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nzeako</surname><given-names>UC</given-names></name><name><surname>Longhurst</surname><given-names>HJ</given-names></name></person-group><article-title>Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema</article-title><source>Eur J Gastroenterol Hepatol</source><year>2012</year><volume>24</volume><issue>4</issue><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">22410711</pub-id></element-citation></ref><ref id="b5-ceg-7-435"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nzeako</surname><given-names>UC</given-names></name></person-group><article-title>Diagnosis and management of angioedema with abdominal involvement: a gastroenterology perspective</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><issue>39</issue><fpage>4913</fpage><lpage>4921</lpage><pub-id pub-id-type="pmid">20954277</pub-id></element-citation></ref><ref id="b6-ceg-7-435"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zilberberg</surname><given-names>MD</given-names></name><name><surname>Nathanson</surname><given-names>BH</given-names></name><name><surname>Jacobsen</surname><given-names>T</given-names></name><name><surname>Tillotson</surname><given-names>G</given-names></name></person-group><article-title>Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006&#x02013;2007</article-title><source>Allergy Asthma Proc</source><year>2011</year><volume>32</volume><issue>5</issue><fpage>390</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">22195693</pub-id></element-citation></ref><ref id="b7-ceg-7-435"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zilberberg</surname><given-names>MD</given-names></name><name><surname>Nathanson</surname><given-names>BH</given-names></name><name><surname>Jacobsen</surname><given-names>T</given-names></name><name><surname>Tillotson</surname><given-names>G</given-names></name></person-group><article-title>Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004&#x02013;2007</article-title><source>Allergy Asthma Proc</source><year>2011</year><volume>32</volume><issue>3</issue><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">21549036</pub-id></element-citation></ref><ref id="b8-ceg-7-435"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lumry</surname><given-names>WR</given-names></name><name><surname>Castaldo</surname><given-names>AJ</given-names></name><name><surname>Vernon</surname><given-names>MK</given-names></name><name><surname>Blaustein</surname><given-names>MB</given-names></name><name><surname>Wilson</surname><given-names>DA</given-names></name><name><surname>Horn</surname><given-names>PT</given-names></name></person-group><article-title>The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression</article-title><source>Allergy Asthma Proc</source><year>2010</year><volume>31</volume><issue>5</issue><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">20929608</pub-id></element-citation></ref><ref id="b9-ceg-7-435"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MM</given-names></name></person-group><article-title>Urticaria and angioedema</article-title><person-group person-group-type="editor"><name><surname>Goldman</surname><given-names>L</given-names></name><name><surname>Bennett</surname><given-names>JC</given-names></name></person-group><source>Cecil Textbook of Medicine</source><edition>21st ed</edition><publisher-loc>Philadelphia, PA, USA</publisher-loc><publisher-name>WB Saunders</publisher-name><year>2000</year></element-citation></ref><ref id="b10-ceg-7-435"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talavera</surname><given-names>A</given-names></name><name><surname>Larraona</surname><given-names>JL</given-names></name><name><surname>Ramos</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Hereditary angioedema: an infrequent cause of abdominal pain with ascites</article-title><source>Am J Gastroenterol</source><year>1995</year><volume>90</volume><issue>3</issue><fpage>471</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">7872288</pub-id></element-citation></ref><ref id="b11-ceg-7-435"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Johnston</surname><given-names>DT</given-names></name></person-group><article-title>Hereditary and acquired complement component 1 esterase inhibitor deficiency: a review for the hematologist</article-title><source>Acta Haematol</source><year>2012</year><volume>127</volume><issue>4</issue><fpage>208</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">22456031</pub-id></element-citation></ref><ref id="b12-ceg-7-435"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>T</given-names></name><name><surname>Baeza</surname><given-names>ML</given-names></name><name><surname>Cabanas</surname><given-names>R</given-names></name><etal/></person-group><article-title>Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations</article-title><source>J Investig Allergol Clin Immunol</source><year>2011</year><volume>21</volume><issue>6</issue><fpage>422</fpage><lpage>441</lpage></element-citation></ref><ref id="b13-ceg-7-435"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>A</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name></person-group><article-title>Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients</article-title><source>Medicine (Baltimore)</source><year>1992</year><volume>71</volume><issue>4</issue><fpage>206</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">1518394</pub-id></element-citation></ref><ref id="b14-ceg-7-435"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gooi</surname><given-names>JHC</given-names></name></person-group><source>Hereditary angioedema: a clinical review for the general physician</source><publisher-loc>Devon, UK</publisher-loc><publisher-name>Priory Lodge Education Limited</publisher-name><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.priory.com/medicine/angioedema.htm">http://www.priory.com/medicine/angioedema.htm</ext-link></comment><date-in-citation>Accessed January 17, 2014</date-in-citation></element-citation></ref><ref id="b15-ceg-7-435"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longhurst</surname><given-names>H</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name></person-group><article-title>Hereditary angio-oedema</article-title><source>Lancet</source><year>2012</year><volume>379</volume><issue>9814</issue><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">22305226</pub-id></element-citation></ref><ref id="b16-ceg-7-435"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cugno</surname><given-names>M</given-names></name><name><surname>Zanichelli</surname><given-names>A</given-names></name><name><surname>Foieni</surname><given-names>F</given-names></name><name><surname>Caccia</surname><given-names>S</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name></person-group><article-title>C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress</article-title><source>Trends Mol Med</source><year>2009</year><volume>15</volume><issue>2</issue><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">19162547</pub-id></element-citation></ref><ref id="b17-ceg-7-435"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalmar</surname><given-names>L</given-names></name><name><surname>Hegedus</surname><given-names>T</given-names></name><name><surname>Farkas</surname><given-names>H</given-names></name><name><surname>Nagy</surname><given-names>M</given-names></name><name><surname>Tordai</surname><given-names>A</given-names></name></person-group><article-title>HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene</article-title><source>Hum Mutat</source><year>2005</year><volume>25</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15580551</pub-id></element-citation></ref><ref id="b18-ceg-7-435"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>T</given-names></name><name><surname>Baeza</surname><given-names>ML</given-names></name><name><surname>Cabanas</surname><given-names>R</given-names></name><etal/></person-group><article-title>Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis</article-title><source>J Investig Allergol Clin Immunol</source><year>2011</year><volume>21</volume><issue>5</issue><fpage>333</fpage><lpage>347</lpage></element-citation></ref><ref id="b19-ceg-7-435"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>B</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Binkley</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel</article-title><source>Allergy Asthma Proc</source><year>2012</year><volume>33</volume><issue>Suppl 1</issue><fpage>S145</fpage><lpage>S156</lpage><pub-id pub-id-type="pmid">23394603</pub-id></element-citation></ref><ref id="b20-ceg-7-435"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniu</surname><given-names>SA</given-names></name></person-group><article-title>Therapeutic approaches in hereditary angioedema</article-title><source>Clin Rev Allergy Immunol</source><year>2011</year><volume>41</volume><issue>1</issue><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">21279474</pub-id></element-citation></ref><ref id="b21-ceg-7-435"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>AE</given-names><suffix>III</suffix></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Mejia</surname><given-names>P</given-names></name></person-group><article-title>C1 inhibitor, a multi-functional serine protease inhibitor</article-title><source>Thromb Haemost</source><year>2010</year><volume>104</volume><issue>5</issue><fpage>886</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">20806108</pub-id></element-citation></ref><ref id="b22-ceg-7-435"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>JH</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>PS</given-names></name></person-group><article-title>The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema</article-title><source>Expert Opin Investig Drugs</source><year>2006</year><volume>15</volume><issue>9</issue><fpage>1077</fpage><lpage>1090</lpage></element-citation></ref><ref id="b23-ceg-7-435"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>JW</given-names></name><name><surname>Shariat-Madar</surname><given-names>Z</given-names></name></person-group><article-title>Human plasma kallikrein-kinin system: physiological and biochemical parameters</article-title><source>Cardiovasc Hematol Agents Med Chem</source><year>2009</year><volume>7</volume><issue>3</issue><fpage>234</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">19689262</pub-id></element-citation></ref><ref id="b24-ceg-7-435"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>AP</given-names></name></person-group><article-title>Kinins, airway obstruction, and anaphylaxis</article-title><source>Chem Immunol Allergy</source><year>2010</year><volume>95</volume><fpage>67</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">20519882</pub-id></element-citation></ref><ref id="b25-ceg-7-435"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>BP</given-names></name></person-group><article-title>Hereditary angioedema: therapies new and old</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>6</issue><fpage>581</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">20818894</pub-id></element-citation></ref><ref id="b26-ceg-7-435"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Dewald</surname><given-names>G</given-names></name></person-group><article-title>Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy</article-title><source>Am J Med</source><year>2003</year><volume>114</volume><issue>4</issue><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">12681457</pub-id></element-citation></ref><ref id="b27-ceg-7-435"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>A</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Cugno</surname><given-names>M</given-names></name><name><surname>Zingale</surname><given-names>LC</given-names></name><name><surname>Gioffr&#x000e9;</surname><given-names>D</given-names></name><name><surname>Nussberger</surname><given-names>J</given-names></name></person-group><article-title>Angioedema due to angiotensin-converting enzyme inhibitors</article-title><source>Immunopharmacology</source><year>1999</year><volume>44</volume><issue>1&#x02013;2</issue><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">10604520</pub-id></element-citation></ref><ref id="b28-ceg-7-435"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>AP</given-names></name></person-group><article-title>Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>126</volume><issue>5</issue><fpage>918</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">20889195</pub-id></element-citation></ref><ref id="b29-ceg-7-435"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MM</given-names></name><name><surname>Gelfand</surname><given-names>JA</given-names></name><name><surname>Atkinson</surname><given-names>JP</given-names></name></person-group><article-title>Hereditary angioedema: the clinical syndrome and its management</article-title><source>Ann Intern Med</source><year>1976</year><volume>84</volume><issue>5</issue><fpage>580</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">1275365</pub-id></element-citation></ref><ref id="b30-ceg-7-435"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Staubach</surname><given-names>P</given-names></name><name><surname>Eckardt</surname><given-names>AJ</given-names></name><name><surname>Hardt</surname><given-names>J</given-names></name></person-group><article-title>Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency</article-title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><issue>3</issue><fpage>619</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">16464219</pub-id></element-citation></ref><ref id="b31-ceg-7-435"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>A</given-names></name><name><surname>Aygoren-Pursun</surname><given-names>E</given-names></name><name><surname>Binkley</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond</article-title><source>J Allergy Clin Immunol</source><year>2004</year><volume>114</volume><issue>Suppl 3</issue><fpage>S51</fpage><lpage>S131</lpage><pub-id pub-id-type="pmid">15356535</pub-id></element-citation></ref><ref id="b32-ceg-7-435"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locascio</surname><given-names>EJ</given-names></name><name><surname>Mahler</surname><given-names>SA</given-names></name><name><surname>Arnold</surname><given-names>TC</given-names></name></person-group><article-title>Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis</article-title><source>West J Emerg Med</source><year>2010</year><volume>11</volume><issue>4</issue><fpage>391</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">21079716</pub-id></element-citation></ref><ref id="b33-ceg-7-435"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohsawa</surname><given-names>I</given-names></name><name><surname>Nagamachi</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Leukocytosis and high hematocrit levels during abdominal attacks of hereditary angioedema</article-title><source>BMC Gastroenterol</source><year>2013</year><volume>13</volume><fpage>123</fpage><pub-id pub-id-type="pmid">23915279</pub-id></element-citation></ref><ref id="b34-ceg-7-435"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Siedlecki</surname><given-names>K</given-names></name><name><surname>Bosch</surname><given-names>S</given-names></name><name><surname>Schopf</surname><given-names>RE</given-names></name><name><surname>Kreuz</surname><given-names>W</given-names></name></person-group><article-title>Asphyxiation by laryngeal edema in patients with hereditary angioedema</article-title><source>Mayo Clin Proc</source><year>2000</year><volume>75</volume><issue>4</issue><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">10761488</pub-id></element-citation></ref><ref id="b35-ceg-7-435"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>H</given-names></name></person-group><article-title>Management of upper airway edema caused by hereditary angioedema</article-title><source>Allergy Asthma Clin Immunol</source><year>2010</year><volume>6</volume><issue>1</issue><fpage>19</fpage><pub-id pub-id-type="pmid">20667122</pub-id></element-citation></ref><ref id="b36-ceg-7-435"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanichelli</surname><given-names>A</given-names></name><name><surname>Magerl</surname><given-names>M</given-names></name><name><surname>Longhurst</surname><given-names>H</given-names></name><name><surname>Fabien</surname><given-names>V</given-names></name><name><surname>Maurer</surname><given-names>M</given-names></name></person-group><article-title>Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe</article-title><source>Allergy Asthma Clin Immunol</source><year>2013</year><volume>9</volume><issue>1</issue><fpage>29</fpage><pub-id pub-id-type="pmid">23937903</pub-id></element-citation></ref><ref id="b37-ceg-7-435"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>H</given-names></name><name><surname>Harmat</surname><given-names>G</given-names></name><name><surname>F&#x000e1;y</surname><given-names>A</given-names></name><etal/></person-group><article-title>Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema</article-title><source>Acta Derm Venereol</source><year>2001</year><volume>81</volume><issue>5</issue><fpage>376</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">11800154</pub-id></element-citation></ref><ref id="b38-ceg-7-435"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name></person-group><article-title>Hereditary angioedema</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>10</issue><fpage>1027</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">18768946</pub-id></element-citation></ref><ref id="b39-ceg-7-435"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>AI</given-names></name><name><surname>De Schepper</surname><given-names>AM</given-names></name><name><surname>Vandevenne</surname><given-names>JE</given-names></name><name><surname>Schoeters</surname><given-names>P</given-names></name><name><surname>Michielsen</surname><given-names>P</given-names></name><name><surname>Stevens</surname><given-names>WJ</given-names></name></person-group><article-title>CT of angioedema of the small bowel</article-title><source>AJR Am J Roentgenol</source><year>2001</year><volume>176</volume><issue>3</issue><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">11222198</pub-id></element-citation></ref><ref id="b40-ceg-7-435"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>H</given-names></name><name><surname>Harmat</surname><given-names>G</given-names></name><name><surname>Kaposi</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema</article-title><source>Eur J Gastroenterol Hepatol</source><year>2001</year><volume>13</volume><issue>10</issue><fpage>1225</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">11711780</pub-id></element-citation></ref><ref id="b41-ceg-7-435"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrosa</surname><given-names>M</given-names></name><name><surname>Caballero</surname><given-names>T</given-names></name><name><surname>G&#x000f3;mez-Traseira</surname><given-names>C</given-names></name><name><surname>Olveira</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Serrano</surname><given-names>C</given-names></name></person-group><article-title>Usefulness of abdominal ultrasonography in the follow-up of patients with hereditary C1-inhibitor deficiency</article-title><source>Ann Allergy Asthma Immunol</source><year>2009</year><volume>102</volume><issue>6</issue><fpage>483</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">19558006</pub-id></element-citation></ref><ref id="b42-ceg-7-435"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinkel</surname><given-names>HP</given-names></name><name><surname>Maroske</surname><given-names>J</given-names></name><name><surname>Schrod</surname><given-names>L</given-names></name></person-group><article-title>Sonographic appearances of the abdominal manifestations of hereditary angioedema</article-title><source>Pediatr Radiol</source><year>2001</year><volume>31</volume><issue>4</issue><fpage>296</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">11321752</pub-id></element-citation></ref><ref id="b43-ceg-7-435"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoxha</surname><given-names>M</given-names></name><name><surname>Meta</surname><given-names>D</given-names></name><name><surname>Kalo</surname><given-names>T</given-names></name></person-group><article-title>Hereditary angioedema as a potential cause of cerebral edema</article-title><source>Otorhinolaryngologia &#x02013; Head and Neck Surgery</source><year>2013</year><volume>51</volume><fpage>31</fpage><lpage>34</lpage></element-citation></ref><ref id="b44-ceg-7-435"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zingale</surname><given-names>LC</given-names></name><name><surname>Zanichelli</surname><given-names>A</given-names></name><name><surname>Deliliers</surname><given-names>DL</given-names></name><name><surname>Rondonotti</surname><given-names>E</given-names></name><name><surname>De Franchis</surname><given-names>R</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name></person-group><article-title>Successful resolution of bowel obstruction in a patient with hereditary angioedema</article-title><source>Eur J Gastroenterol Hepatol</source><year>2008</year><volume>20</volume><issue>6</issue><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">18467921</pub-id></element-citation></ref><ref id="b45-ceg-7-435"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gompels</surname><given-names>MM</given-names></name><name><surname>Lock</surname><given-names>RJ</given-names></name><name><surname>Morgan</surname><given-names>JE</given-names></name><name><surname>Osborne</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Virgo</surname><given-names>PF</given-names></name></person-group><article-title>A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency</article-title><source>J Clin Pathol</source><year>2002</year><volume>55</volume><issue>2</issue><fpage>145</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">11865013</pub-id></element-citation></ref><ref id="b46-ceg-7-435"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gompels</surname><given-names>MM</given-names></name><name><surname>Lock</surname><given-names>RJ</given-names></name><name><surname>Abinun</surname><given-names>M</given-names></name><etal/></person-group><article-title>C1 inhibitor deficiency: consensus document</article-title><source>Clin Exp Immunol</source><year>2005</year><volume>139</volume><issue>3</issue><fpage>379</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">15730382</pub-id></element-citation></ref><ref id="b47-ceg-7-435"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>T</given-names></name></person-group><article-title>Hereditary Angioedema Consensus 2010</article-title><source>Allergy Asthma Clin Immunol</source><year>2010</year><volume>6</volume><issue>1</issue><fpage>13</fpage><pub-id pub-id-type="pmid">20667116</pub-id></element-citation></ref><ref id="b48-ceg-7-435"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name></person-group><article-title>Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor</article-title><source>Allergy Asthma Clin Immunol</source><year>2010</year><volume>6</volume><issue>1</issue><fpage>15</fpage><pub-id pub-id-type="pmid">20667118</pub-id></element-citation></ref><ref id="b49-ceg-7-435"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eidelman</surname><given-names>FJ</given-names></name></person-group><article-title>Hereditary angioedema: New therapeutic options for a potentially deadly disorder</article-title><source>BMC Blood Disord</source><year>2010</year><volume>10</volume><fpage>3</fpage><pub-id pub-id-type="pmid">20470390</pub-id></element-citation></ref><ref id="b50-ceg-7-435"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>T</given-names></name><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Farkas</surname><given-names>H</given-names></name><etal/></person-group><article-title>2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema</article-title><source>Allergy Asthma Clin Immunol</source><year>2010</year><volume>6</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="pmid">20667127</pub-id></element-citation></ref><ref id="b51-ceg-7-435"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>T</given-names></name><name><surname>Sala-Cunill</surname><given-names>A</given-names></name><name><surname>Cancian</surname><given-names>M</given-names></name><etal/></person-group><article-title>Current status of implementation of self-administration training in various regions of Europe, Canada and the USA in the management of hereditary angioedema</article-title><source>Int Arch Allergy Immunol</source><year>2013</year><volume>161</volume><issue>Suppl 1</issue><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">23689239</pub-id></element-citation></ref><ref id="b52-ceg-7-435"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedl</surname><given-names>MA</given-names></name></person-group><article-title>Creating a comprehensive treatment plan for hereditary angioedema</article-title><source>Immunol Allergy Clin N Am</source><year>2013</year><volume>33</volume><issue>4</issue><fpage>471</fpage><lpage>485</lpage></element-citation></ref><ref id="b53-ceg-7-435"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>T</given-names></name><name><surname>Ayg&#x000f6;ren-P&#x000fc;rs&#x000fc;n</surname><given-names>E</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><etal/></person-group><article-title>WAO guideline for the management of hereditary angioedema</article-title><source>World Allergy Organ J</source><year>2012</year><volume>5</volume><issue>12</issue><fpage>182</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">23282420</pub-id></element-citation></ref><ref id="b54-ceg-7-435"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicardi</surname><given-names>M</given-names></name><name><surname>Bork</surname><given-names>K</given-names></name><name><surname>Caballero</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group</article-title><source>Allergy</source><year>2012</year><volume>67</volume><issue>2</issue><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">22126399</pub-id></element-citation></ref><ref id="b55-ceg-7-435"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerji</surname><given-names>A</given-names></name></person-group><article-title>Current treatment of hereditary angioedema: an update on clinical studies</article-title><source>Allergy Asthma Proc</source><year>2010</year><volume>31</volume><issue>5</issue><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">20929607</pub-id></element-citation></ref><ref id="b56-ceg-7-435"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Temino</surname><given-names>VM</given-names></name><name><surname>Peebles</surname><given-names>RS</given-names><suffix>Jr</suffix></name></person-group><article-title>The spectrum and treatment of angioedema</article-title><source>Am J Med</source><year>2008</year><volume>121</volume><issue>4</issue><fpage>282</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">18374684</pub-id></element-citation></ref><ref id="b57-ceg-7-435"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name><name><surname>Lang</surname><given-names>DM</given-names></name><etal/><collab>American Academy of Allergy, Asthma and Immunology</collab><collab>American College of Allergy, Asthma and Immunology</collab></person-group><article-title>A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema</article-title><source>J Allergy Clin Immunol</source><year>2013</year><volume>131</volume><issue>6</issue><fpage>1491</fpage><lpage>1493</lpage><pub-id pub-id-type="pmid">23726531</pub-id></element-citation></ref><ref id="b58-ceg-7-435"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>TG</given-names></name><name><surname>Bernstein</surname><given-names>JA</given-names></name></person-group><article-title>Current and emerging management options for hereditary angioedema in the US</article-title><source>Drugs</source><year>2008</year><volume>68</volume><issue>18</issue><fpage>2561</fpage><lpage>2573</lpage><pub-id pub-id-type="pmid">19093699</pub-id></element-citation></ref><ref id="b59-ceg-7-435"><label>59</label><element-citation publication-type="book"><source>Berinert [C1 esterase inhibitor (human)] package insert</source><publisher-loc>Kankakee, IL, USA</publisher-loc><publisher-name>CSL Behring</publisher-name><year>2011</year></element-citation></ref><ref id="b60-ceg-7-435"><label>60</label><element-citation publication-type="book"><source>Cinryze (C1 esterase inhibitor) package insert</source><publisher-loc>Exton, PA, USA</publisher-loc><publisher-name>ViroPharma Biologics</publisher-name><year>2012</year></element-citation></ref><ref id="b61-ceg-7-435"><label>61</label><element-citation publication-type="book"><source>Cetor (C1 esterase inhibitor) 500 U powder and solvent for solution for injection (package leaflet)</source><publisher-loc>Amsterdam, The Netherlands</publisher-loc><publisher-name>Sanquin Blood Supply Foundation</publisher-name><year>2003</year></element-citation></ref><ref id="b62-ceg-7-435"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>L</given-names></name><name><surname>Farkas</surname><given-names>H</given-names></name></person-group><article-title>rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency</article-title><source>Expert Rev Clin Immunol</source><year>2011</year><volume>7</volume><issue>2</issue><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">21426252</pub-id></element-citation></ref><ref id="b63-ceg-7-435"><label>63</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Ruconest (Rhucin in non-European territories)</collab></person-group><source>Recombinant human C1 esterase inhibitor</source><publisher-loc>Pharming</publisher-loc><publisher-name>Leiden, the Netherlands</publisher-name><year>2013</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.pharming.com/index.php?act=prod">http://www.pharming.com/index.php?act=prod</ext-link></comment><date-in-citation>Accessed February 17, 2014</date-in-citation></element-citation></ref><ref id="b64-ceg-7-435"><label>64</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Santarus</collab></person-group><source>Santarus and Pharming announce FDA acceptance for review of Ruconest (recombinant human C1 esterase inhibitor) Biologics License Application</source><month>6</month><day>18</day><year>2013</year><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.businesswire.com/news/home/20130617006581/en/Santarus-Pharming-Announce-FDA-Acceptance-Review-RUCONEST#.UtlxG50o7IU">http://www.businesswire.com/news/home/20130617006581/en/Santarus-Pharming-Announce-FDA-Acceptance-Review-RUCONEST#.UtlxG50o7IU</ext-link></comment><date-in-citation>Accessed January 17, 2014</date-in-citation><date-in-citation>Accessed October 8, 2013</date-in-citation></element-citation></ref><ref id="b65-ceg-7-435"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunn</surname><given-names>M</given-names></name><name><surname>Banta</surname><given-names>E</given-names></name></person-group><article-title>Ecallantide for the treatment of hereditary angiodema in adults</article-title><source>Clin Med Insights Cardiol</source><year>2011</year><volume>5</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">21695090</pub-id></element-citation></ref><ref id="b66-ceg-7-435"><label>66</label><element-citation publication-type="book"><source>Kalbitor (ecallantide) package insert</source><publisher-loc>Burlington, MA, USA</publisher-loc><publisher-name>Dyax Corp</publisher-name><year>2012</year></element-citation></ref><ref id="b67-ceg-7-435"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>RJ</given-names></name><name><surname>Lumry</surname><given-names>WR</given-names></name><name><surname>McNeil</surname><given-names>DL</given-names></name><etal/></person-group><article-title>EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema</article-title><source>Ann Allergy Asthma Immunol</source><year>2010</year><volume>104</volume><issue>6</issue><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">20568386</pub-id></element-citation></ref><ref id="b68-ceg-7-435"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>EA</given-names></name><name><surname>Cohen</surname><given-names>AF</given-names></name></person-group><article-title>Icatibant</article-title><source>Br J Clin Pharmacol</source><year>2010</year><volume>69</volume><issue>5</issue><fpage>425</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">20573077</pub-id></element-citation></ref><ref id="b69-ceg-7-435"><label>69</label><element-citation publication-type="book"><source>Firazyr (icatibant) package insert</source><publisher-loc>Lexington, MA</publisher-loc><publisher-name>Shire Orphan Therapies, Inc</publisher-name><year>2011</year></element-citation></ref><ref id="b70-ceg-7-435"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>PW</given-names></name><name><surname>Hirschl</surname><given-names>MM</given-names></name><name><surname>Trautinger</surname><given-names>F</given-names></name></person-group><article-title>Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>63</volume><issue>5</issue><fpage>913</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">20554347</pub-id></element-citation></ref><ref id="b71-ceg-7-435"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prematta</surname><given-names>M</given-names></name><name><surname>Gibbs</surname><given-names>JG</given-names></name><name><surname>Pratt</surname><given-names>EL</given-names></name><name><surname>Stoughton</surname><given-names>TR</given-names></name><name><surname>Craig</surname><given-names>TJ</given-names></name></person-group><article-title>Fresh frozen plasma for the treatment of hereditary angioedema</article-title><source>Ann Allergy Asthma Immunol</source><year>2007</year><volume>98</volume><issue>4</issue><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">17458436</pub-id></element-citation></ref><ref id="b72-ceg-7-435"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longhurst</surname><given-names>HJ</given-names></name></person-group><article-title>Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?</article-title><source>Int J Clin Pract</source><year>2005</year><volume>59</volume><issue>5</issue><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">15857357</pub-id></element-citation></ref><ref id="b73-ceg-7-435"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekdemir</surname><given-names>M</given-names></name><name><surname>Ersel</surname><given-names>M</given-names></name><name><surname>Aksay</surname><given-names>E</given-names></name><name><surname>Yanturali</surname><given-names>S</given-names></name><name><surname>Akturk</surname><given-names>A</given-names></name><name><surname>Kiyan</surname><given-names>S</given-names></name></person-group><article-title>Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department</article-title><source>J Emerg Med</source><year>2007</year><volume>33</volume><issue>2</issue><fpage>137</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">17692764</pub-id></element-citation></ref><ref id="b74-ceg-7-435"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drouet</surname><given-names>C</given-names></name><name><surname>Desormeaux</surname><given-names>A</given-names></name><name><surname>Robillard</surname><given-names>J</given-names></name><etal/></person-group><article-title>Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P</article-title><source>J Allergy Clin Immunol</source><year>2008</year><volume>121</volume><issue>2</issue><fpage>429</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">18158172</pub-id></element-citation></ref><ref id="b75-ceg-7-435"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bork</surname><given-names>K</given-names></name></person-group><article-title>Current management options for hereditary angioedema</article-title><source>Curr Allergy Asthma Rep</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">22729959</pub-id></element-citation></ref><ref id="b76-ceg-7-435"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MM</given-names></name></person-group><article-title>Update on preventive therapy (prophylaxis) of hereditary angioedema</article-title><source>Allergy Asthma Proc</source><year>2011</year><volume>32</volume><issue>1</issue><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21262094</pub-id></element-citation></ref><ref id="b77-ceg-7-435"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloane</surname><given-names>DE</given-names></name><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Sheffer</surname><given-names>AL</given-names></name></person-group><article-title>Hereditary angioedema: Safety of long-term stanozolol therapy</article-title><source>J Allergy Clin Immunol</source><year>2007</year><volume>120</volume><issue>3</issue><fpage>654</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">17765757</pub-id></element-citation></ref><ref id="b78-ceg-7-435"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuraw</surname><given-names>BL</given-names></name><name><surname>Busse</surname><given-names>PJ</given-names></name><name><surname>White</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>6</issue><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">20818886</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ceg-7-435" position="float"><label>Figure 1</label><caption><p>Dysregulation of coagulation, complement, and contact cascades in hereditary angioedema.</p><p><bold>Notes:</bold> C1 inhibitor controls activation in the complement, coagulation, and contact cascades, and all three cascades are dysregulated in hereditary angioedema. Replacement of C1 inhibitor restores homeostasis. Ecallantide and icatibant specifically inhibit the contact cascade but have no direct effect on the complement or coagulation cascades.<xref rid="b25-ceg-7-435" ref-type="bibr">25</xref> Dashed arrows indicate enzyme cleavage steps; T bars indicate points of inhibition. Reprinted from The New England Journal of Medicine, Morgan BP. Hereditary angioedema: therapies new and old. <italic>N Engl J Med.</italic> 2010;363(6):581&#x02013;583. Copyright &#x000a9; 2010 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.<xref rid="b25-ceg-7-435" ref-type="bibr">25</xref></p><p><bold>Abbreviations:</bold> HAE, hereditary angioedema; MASP-2, mannose-binding lectin-associated serine protease 2.</p></caption><graphic xlink:href="ceg-7-435Fig1"/></fig><fig id="f2-ceg-7-435" position="float"><label>Figure 2</label><caption><p>Sites affected by angioedema in patients with clinical symptoms of hereditary angioedema.</p><p><bold>Notes:</bold> Reprinted from The American Journal of Medicine. Volume 119(3), Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course pages 267&#x02013;274; Copyright &#x000a9; 2006, with permission from Elsevier.<xref rid="b2-ceg-7-435" ref-type="bibr">2</xref></p></caption><graphic xlink:href="ceg-7-435Fig2"/></fig><fig id="f3-ceg-7-435" position="float"><label>Figure 3</label><caption><p>Phases and time course for typical abdominal pain attacks in patients with hereditary angioedema.</p><p><bold>Notes:</bold> Reprinted by permission from Macmillan Publishers Ltd on behalf of <italic>American Journal of Gastroenterology.</italic> Copyright &#x000a9; 2006. Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in HAE to C1 inhibitor deficiency. <italic>Am J Gastroenterol.</italic> 2006;101(3):619&#x02013;627.<xref rid="b30-ceg-7-435" ref-type="bibr">30</xref></p></caption><graphic xlink:href="ceg-7-435Fig3"/></fig><fig id="f4-ceg-7-435" position="float"><label>Figure 4</label><caption><p>Abdominal computed tomography scan of patient with hereditary angioedema showing thickening of the small bowel (stacked-coin appearance) due to angioedema.</p><p><bold>Notes:</bold> Curved arrow indicates prominent fold thickening; straight arrows indicate pelvic ascites. Reprinted with permission from the <italic>American Journal of Roentgenology</italic>. De Backer AI, De Schepper AM, Vandevenne JE, Schoeters P, Michielsen P, Stevens WJ. CT of angioedema of the small bowel. <italic>Am J Roentgenol.</italic> 2001;176(3):649&#x02013;652.<xref rid="b39-ceg-7-435" ref-type="bibr">39</xref></p></caption><graphic xlink:href="ceg-7-435Fig4"/></fig><fig id="f5-ceg-7-435" position="float"><label>Figure 5</label><caption><p>Diagnostic algorithm for hereditary angioedema.</p><p><bold>Notes:</bold> From Bowen T, Cicardi M, Farkas H, et al. 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. <italic>Allergy Asthma Clin Immunol.</italic> 2010;6(1):24.<xref rid="b50-ceg-7-435" ref-type="bibr">50</xref></p><p><bold>Abbreviations:</bold> AE, adverse event; ACE, angiotensin-converting enzyme; C1-INH, C1 esterase inhibitor; C1q, complement component 1, q subcomponent; HAE, hereditary angioedema.</p></caption><graphic xlink:href="ceg-7-435Fig5"/></fig><table-wrap id="t1-ceg-7-435" position="float"><label>Table 1</label><caption><p>Differential diagnosis of intestinal angioedema</p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Initial presentation</td><td valign="top" align="left" rowspan="1" colspan="1">Colicky abdominal pain, nausea, and vomiting</td></tr><tr><td rowspan="5" valign="top" align="left" colspan="1">Possible gastrointestinal disorders</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Appendicitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Hepatitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Pancreatitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Biliary obstruction</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Diverticulitis</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Test results</bold></td></tr><tr><td rowspan="5" valign="top" align="left" colspan="1">Biochemical</td><td valign="top" align="left" rowspan="1" colspan="1">Suggestive of HAE</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; C1-INH level of &#x0003c;21 mg/dL</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Decreased C2 and C4 levels</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rules out biliary obstruction and hepatitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Normal serum bilirubin, ALP, and ALT levels</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Ultrasonography</td><td valign="top" align="left" rowspan="1" colspan="1">Suggestive of HAE</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Bowel mucosal thickening</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Ascites</td></tr><tr><td rowspan="9" valign="top" align="left" colspan="1">Computed tomography</td><td valign="top" align="left" rowspan="1" colspan="1">Suggestive of HAE</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Massive small bowel or colonic edema</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Prominent mesenteric vessels</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Thickened omentum</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Moderate ascites</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rules out appendicitis and diverticulitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Normal pericolic fat</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rules out pancreatitis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Normally shaped pancreas</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ceg-7-435"><p><bold>Notes:</bold> Data from Bork, Fischer, and Dewald;<xref rid="b26-ceg-7-435" ref-type="bibr">26</xref> and Bork, Staubach, and Eckardt.<xref rid="b30-ceg-7-435" ref-type="bibr">30</xref> Reproduced from Locascio EJ, Mahler SA, Arnold TC. Intestinal angioedema misdiagnosed as recurrent episodes of gastroenteritis. <italic>West J Emerg Med</italic>. 2010;11(4): 391&#x02013;394.<xref rid="b32-ceg-7-435" ref-type="bibr">32</xref></p></fn><fn id="tfn2-ceg-7-435"><p><bold>Abbreviations:</bold> ALP, alkaline phosphatase; ALT, alanine aminotransferase; C1-INH, C1 esterase inhibitor; HAE, hereditary angioedema.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ceg-7-435" position="float"><label>Table 2</label><caption><p>Hereditary Angioedema International Working Group consensus guidelines for the management of hereditary angioedema</p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Recommendations for acute treatment</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1. All patients should have access to plasma-derived and recombinant C1-INH, icatibant, and ecallantide</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2. Patients should keep medications at home and be trained to self-administer them</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3. All attacks, regardless of their location on the body, should be treated as soon as recognized</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4. Patients should report to a hospital if laryngeal symptoms persist following initial treatment</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Recommendations for prophylactic treatment</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1. Long-term prophylaxis is appropriate for patients in whom on-demand treatment is inadequate to control the disease</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2. Androgens can be used in patients aged &#x0003e;16 years, and in women who are not pregnant or lactating</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3. Androgens are not recommended if not tolerated by the patient or if the effective dose of danazol exceeds 200 mg/day</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4. All patients can be considered for plasma-derived C1-INH</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5. Treatment with plasma-derived C1-INH should be individualized to optimize clinical response</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ceg-7-435"><p><bold>Note:</bold> Data from Cicardi et al.<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref></p></fn><fn id="tfn4-ceg-7-435"><p><bold>Abbreviation:</bold> C1-INH, C1 esterase inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ceg-7-435" position="float"><label>Table 3</label><caption><p>Specific agents for hereditary angioedema (HAE)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Drug (Trade name; manufacturer)</th><th valign="top" align="left" rowspan="1" colspan="1">Approval for HAE</th><th valign="top" align="left" rowspan="1" colspan="1">Age group</th><th valign="top" align="left" rowspan="1" colspan="1">Dosage</th><th valign="top" align="left" rowspan="1" colspan="1">Mechanism</th><th valign="top" align="left" rowspan="1" colspan="1">Adverse events</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Plasma-derived nanofiltered C1-INH (Berinert<sup>&#x000ae;</sup> P; CSL Behring, Kankakee, IL, USA)<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref>,<xref rid="b58-ceg-7-435" ref-type="bibr">58</xref>,<xref rid="b59-ceg-7-435" ref-type="bibr">59</xref></td><td valign="top" align="left" rowspan="1" colspan="1">In USA for acute facial, laryngeal, and abdominal attacks<break/>In Europe for all acute attacks and preprocedure prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">Adolescents and adults</td><td valign="top" align="left" rowspan="1" colspan="1">20 U/kg IV</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of plasma kallikrein, coagulation factors XIIa, and XIa, C1s, C1r, MASP-1, MASP-2, and plasmin</td><td valign="top" align="left" rowspan="1" colspan="1">Rare: risk of anaphylaxis<break/>Theoretical: transmission of infectious agent</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Plasma-derived nanofiltered C1-INH (Cinryze<sup>&#x000ae;</sup>; ViroPharma Biologics, Exton, PA, USA)<xref rid="b38-ceg-7-435" ref-type="bibr">38</xref>,<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref>,<xref rid="b60-ceg-7-435" ref-type="bibr">60</xref></td><td valign="top" align="left" rowspan="1" colspan="1">In USA for routine prophylaxis<break/>In Europe for all acute attacks and short-term and long-term prophylaxis</td><td valign="top" align="left" rowspan="1" colspan="1">Adolescents and adults</td><td valign="top" align="left" rowspan="1" colspan="1">1000 U IV every 3&#x02013;4 days</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of plasma kallikrein, coagulation factors XIIa, and XIa, C1s, C1r, MASP-1, MASP-2, and plasmin</td><td valign="top" align="left" rowspan="1" colspan="1">Rare: risk of anaphylaxis<break/>Theoretical: transmission of infectious agent</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant human C1-INH (Ruconest<sup>&#x000ae;</sup>; Pharming Group NV, Leiden, the Netherlands)<xref rid="b38-ceg-7-435" ref-type="bibr">38</xref>,<xref rid="b62-ceg-7-435" ref-type="bibr">62</xref>&#x02013;<xref rid="b64-ceg-7-435" ref-type="bibr">64</xref></td><td valign="top" align="left" rowspan="1" colspan="1">In Europe for acute attacks<break/>In USA, not yet approved, orphan drug, fast track status for acute attacks</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">50&#x02013;100 U/kg IV</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of plasma kallikrein, coagulation factors XIIa, and XIa, C1s, C1r, MASP-1, MASP-2, and plasmin</td><td valign="top" align="left" rowspan="1" colspan="1">Uncommon: risk of anaphylaxis in rabbit-sensitized patients</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant protein, ecallantide (Kalbitor; Dyax Corp, Burlington, MA, USA)<xref rid="b66-ceg-7-435" ref-type="bibr">66</xref>,<xref rid="b67-ceg-7-435" ref-type="bibr">67</xref></td><td valign="top" align="left" rowspan="1" colspan="1">In USA for acute attacks</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;16 years</td><td valign="top" align="left" rowspan="1" colspan="1">30 mg SC (3 injections of 10 mg each)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of plasma kallikrein</td><td valign="top" align="left" rowspan="1" colspan="1">Uncommon: risk of anaphylaxis; antidrug antibodies</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bradykinin B2 receptor antagonist, icatibant (Firazyr<sup>&#x000ae;</sup>; Shire Orphan Therapies, Inc, Lexington, MA, USA)<xref rid="b68-ceg-7-435" ref-type="bibr">68</xref>&#x02013;<xref rid="b70-ceg-7-435" ref-type="bibr">70</xref></td><td valign="top" align="left" rowspan="1" colspan="1">In USA and Europe for acute attacks</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;18 years</td><td valign="top" align="left" rowspan="1" colspan="1">30 mg SC</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of bradykinin</td><td valign="top" align="left" rowspan="1" colspan="1">Common: injection site reactions</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-ceg-7-435"><p><bold>Notes:</bold> Data from Cicardi et al;<xref rid="b54-ceg-7-435" ref-type="bibr">54</xref> Epstein and Bernstein;<xref rid="b58-ceg-7-435" ref-type="bibr">58</xref> Berinert [C1 esterase inhibitor (human)] package insert;<xref rid="b59-ceg-7-435" ref-type="bibr">59</xref> Varga and Farkas;<xref rid="b62-ceg-7-435" ref-type="bibr">62</xref> Ruconest (Rhucin in non-European territories). Recombinant human C1 esterase inhibitor;<xref rid="b63-ceg-7-435" ref-type="bibr">63</xref> Santarus Biologics License Application;<xref rid="b64-ceg-7-435" ref-type="bibr">64</xref> Kalbitor (ecallantide) package insert;<xref rid="b66-ceg-7-435" ref-type="bibr">66</xref> Levy et al;<xref rid="b67-ceg-7-435" ref-type="bibr">67</xref> Dubois and Cohen;<xref rid="b68-ceg-7-435" ref-type="bibr">68</xref> Firazyr (icatibant) package insert,<xref rid="b69-ceg-7-435" ref-type="bibr">69</xref> and Schmidt, Hirschl, Trautinger.<xref rid="b70-ceg-7-435" ref-type="bibr">70</xref> From <italic>The New England Journal of Medicine</italic>, Zuraw BL, Hereditary Angioedema, Volume 359, pp 1027&#x02013;1036. Copyright &#x000a9; 2008 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society.<xref rid="b38-ceg-7-435" ref-type="bibr">38</xref></p></fn><fn id="tfn6-ceg-7-435"><p><bold>Abbreviations:</bold> C1-INH, C1 esterase inhibitor; C1r, complement component 1, r subcomponent; C1s, complement component 1, s subcomponent; IV, intravenous; MASP, mannose-binding lectin serine protease; NR, not reported; SC, subcutaneous.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
